NASDAQ:IMUX Immunic Q1 2026 Earnings Report $9.37 -1.47 (-13.56%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$9.44 +0.07 (+0.77%) As of 05:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immunic EPS ResultsActual EPS-$1.08Consensus EPS -$0.71Beat/MissMissed by -$0.37One Year Ago EPSN/AImmunic Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmunic Announcement DetailsQuarterQ1 2026Date5/13/2026TimeAfter Market ClosesConference Call DateWednesday, May 13, 2026Conference Call Time7:00AM ETUpcoming EarningsImmunic's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunic Earnings HeadlinesImmunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis TranscriptSeptember 11, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and UnitedHealth (UNH)September 11, 2026 | theglobeandmail.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Immunic to host virtual relapsing MS R&D Day on September 9September 2, 2026 | proactiveinvestors.comImmunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026September 2, 2026 | prnewswire.comImmunic Appoints Chitrang Davé as Chief Data and Digital OfficerSeptember 1, 2026 | prnewswire.comSee More Immunic Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunic and other key companies, straight to your email. Email Address About ImmunicImmunic (NASDAQ:IMUX) (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for chronic inflammatory and neurodegenerative diseases. The company’s research programs are designed to address conditions affecting the immune system and central nervous system, including multiple sclerosis and selected gastrointestinal disorders. Immunic’s lead investigational product is vidofludimus calcium, also known as IMU-838, a selective oral inhibitor of the enzyme dihydroorotate dehydrogenase. The therapy has been evaluated in clinical studies for relapsing and progressive forms of multiple sclerosis. Immunic is also advancing earlier-stage programs, including oral drug candidates intended to modulate biological pathways involved in intestinal disease and tissue repair. The company was established in 2016 and operates internationally, with corporate activities in the United States and research and development operations in Europe, particularly Germany. Immunic is led by Chief Executive Officer and co-founder Daniel Vitt, Ph.D. Its products remain investigational, and the company does not currently have an approved commercial product.View Immunic ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
